Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer

被引：8

作者：

Caine, GJ

Harris, AL

Christodoulos, K

Lip, GYH

Blann, AD ^{[1
]}

机构：

[1] Univ Dept Med, City Hosp, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England

[2] Churchill Hosp, Canc Res UK, Med Oncol Unit, Oxford OX3 7LJ, England

来源：

CANCER LETTERS | 2005年 / 219卷 / 02期

关键词：

angiogenesis; platelets; soluble P-selectin; tissue factor; VEGF;

D O I：

10.1016/j.canlet.2004.09.036

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The effects of combination anti-angiogenesis therapy (marimastat, captopril and fragmin) on plasma levels of coagulation initiator tissue factor (TF), platelet marker soluble P-selectin and angiogenic vascular endothelial growth factor (VEGF) were tested in 25 patients with advanced cancer. They had higher soluble P-selectin (P < 0.001) and TF (P < 0.001), but not VEGF (P = 0.066) than 25 age and sex-matched controls. VEGF and TF correlated significantly (r = 0.8, P < 0.001) in cancer patients. Soluble P-selectin, TF and VEGF did not change at 4- and 8-weeks whilst on treatment. We provide further evidence linking coagulation and angiogenesis but combination anti-angiogenesis therapy does not influence plasma soluble P-selectin,TF or VEGF. (c) 2004 Published by Elsevier Ireland Ltd.

引用

收藏

页码：163 / 167

页数：5

相关论文

共 32 条

[11] ANGIOGENESIS INHIBITION AND TUMOR-REGRESSION CAUSED BY HEPARIN OR A HEPARIN FRAGMENT IN THE PRESENCE OF CORTISONE [J].

FOLKMAN, J ;

LANGER, R ;

LINHARDT, RJ ;

HAUDENSCHILD, C ;

TAYLOR, S .

SCIENCE, 1983, 221 (4612) :719-725

[12] Tissue specific expression and serum levels of human tissue factor in patients with urological cancer [J].

Förster, Y ;

Meye, A ;

Albrecht, S ;

Kotzsch, M ;

Füssel, S ;

Wirth, MP ;

Schwenzer, B .

CANCER LETTERS, 2003, 193 (01) :65-73

[13] Soluble P-selectin is influenced by cancer chemotherapy [J].

Gurney, D ;

Poole, C ;

Kehoe, S ;

Lip, GYH ;

Blann, AD .

PLATELETS, 2001, 12 (01) :37-38

[14] Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma [J].

Hii, SI ;

Nicol, DL ;

Gotley, DC ;

Thompson, LC ;

Green, MK ;

Jonsson, JR .

BRITISH JOURNAL OF CANCER, 1998, 77 (06) :880-883

[15] Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients [J].

Kuenen, BC ;

Levi, M ;

Meijers, JCM ;

Kakkar, AK ;

van Hinsbergh, VWM ;

Kostense, PJ ;

Pinedo, HM ;

Hoekman, K .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (09) :1500-1505

[16] Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer [J].

Lin, SY ;

Wang, YY ;

Sheu, WHH .

CLINICAL ENDOCRINOLOGY, 2003, 58 (04) :513-518

[17] Cancer and the prothrombotic state [J].

Lip, GYH ;

Chin, BSP ;

Blann, AD .

LANCET ONCOLOGY, 2002, 3 (01) :27-34

[18]

Macaulay VM, 1999, CLIN CANCER RES, V5, P513

[19] Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets [J].

Müller, I ;

Klocke, A ;

Alex, M ;

Kotzsch, M ;

Luther, T ;

Morgenstern, E ;

Zieseniss, S ;

Zahler, S ;

Preissner, K ;

Engelmann, B .

FASEB JOURNAL, 2003, 17 (01) :476-+

[20] Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer [J].

Nakasaki, T ;

Wada, H ;

Shigemori, C ;

Miki, C ;

Gabazza, EC ;

Nobori, T ;

Nakamura, S ;

Shiku, H .

AMERICAN JOURNAL OF HEMATOLOGY, 2002, 69 (04) :247-254

← 1 2 3 4 →